Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-30

Nurix Therapeutics (NRIX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$6,374,138
Arthur Sands total, FY2025
67th
CEO pay percentile vs peers
23:1
CEO-to-median pay ratio
91.31%
Say-on-pay support, latest vote
Companies that benchmark against NRIX
6 companies name NRIX as a compensation peer

Each company listed discloses NRIX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NRIX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Arthur Sands$674,584$0$0$5,166,196$510,000$0$23,358$6,374,138
President, Chief Executive Officer and Director
Gwenn Hansen556,0000770,816861,033307,44002,8352,498,124
Chief Scientific Officer
Hans van Houte545,8330587,216861,033298,23804,1832,296,503
Chief Financial Officer
Christine Ring527,5000587,216861,033283,81503,7732,263,337
Chief Legal Officer and Chief Compliance Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Arthur Sands$6,374,138$5,812,862$4,363,120+561,276
Gwenn Hansen2,498,1242,033,8601,632,757+464,264
Hans van Houte2,296,5032,016,4821,611,987+280,021
Christine Ring2,263,3372,016,484+246,853

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Christine RingChief Legal Officer2026-04-02D8,148$15$124,149Common, open-market saleForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30A2,00000CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30A3,75000CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30D2,3881739,749Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-04-30A2,00000CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30D2,85800Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-04-30D3,2141753,498Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-04-30D2,00000Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30D2,85800Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30A2,85800CommonForm 4 ↗
Christine RingChief Legal Officer2026-04-30A3,75000CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30D3,2141753,498Common, open-market saleForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30A2,85800CommonForm 4 ↗
Christine RingChief Legal Officer2026-04-30A2,85800CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30D2,00000Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30D3,75000Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-04-30D3,75000Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30A3,75000CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30D2,00000Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-04-30A2,00000CommonForm 4 ↗
Christine RingChief Legal Officer2026-04-30D2,85800Derivative, Class A CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-04-30D3,75000Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-05-01D5,3941790,407Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-05-04D8,14817138,210Common, open-market saleForm 4 ↗
Hans van HouteChief Financial Officer2026-05-05D582179,996Common, open-market saleForm 4 ↗
Hans van HouteChief Financial Officer2026-05-05D13,47317223,323Common, open-market saleForm 4 ↗
Julia P. GregoryDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Roy D. BaynesDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Paul M. SilvaDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Edward C. SaltzmanDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Anil KapurDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Judith A. ReinsdorfDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
David L. LaceyDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Roger DanseyDirector2026-05-15A31,25000Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-02D3,42200Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-02D8,14817135,253Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-06-02A3,42226,365CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-06-25D5,39420107,880CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-25D28,93520580,506Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-06-25D15,60200Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-25A15,6029136,049CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-25A13,333796,798CommonForm 4 ↗
Christine RingChief Legal Officer2026-06-25D13,33300Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-02A5,787950,463CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-02D5,22100Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-02D11,00824259,366Common, open-market saleForm 4 ↗
Christine RingChief Legal Officer2026-07-02A5,22129,711CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-02D5,78700Derivative, Class A CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30A3,57200CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30A3,75000CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30D2,85800Derivative, Class A CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30D3,57200Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30D3,75000Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30D3,8472389,954Common, open-market saleForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30D3,8472389,954Common, open-market saleForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30A3,57200CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30D2,85800Derivative, Class A CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30D3,57200Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30D2,85800Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30D3,57200Derivative, Class A CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30A3,57200CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30A2,85800CommonForm 4 ↗
Christine RingChief Legal Officer2026-07-30A3,75000CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30A2,85800CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30D3,75000Derivative, Class A CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30D3,75000Derivative, Class A CommonForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30D2,8452366,524Common, open-market saleForm 4 ↗
Hans van HouteChief Financial Officer2026-07-30A2,85800CommonForm 4 ↗
Gwenn HansenChief Scientific Officer2026-07-30A3,75000CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Gwenn HansenOPTION2025-02-1175,000$861,033
Gwenn HansenRSU2025-02-1134,300587,216
Arthur SandsOPTION2025-02-11450,0005,166,196
Gwenn HansenRSU2025-10-1420,000183,600
Christine RingRSU2025-02-1134,300587,216
Christine RingOPTION2025-02-1175,000861,033
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Gwenn Hansen$770,816$0$861,0330.0%
Arthur Sands005,166,1960.0%
Christine Ring587,2160861,0330.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Arthur SandsOption337,50017.12
Arthur SandsOption37,33410.83
Hans van HouteRSU28,584505,365
Gwenn HansenRSU4,00070,720
Christine RingRSU28,584505,365
Christine RingOption56,25017.12
Gwenn HansenRSU28,584505,365
Christine RingOption62,5008.72
Hans van HouteOption56,25017.12
Hans van HouteOption22,50018.5
Gwenn HansenRSU22,500397,800
Gwenn HansenOption7,40910.83
Gwenn HansenRSU3,20756,700
Gwenn HansenOption4,81019.49
Gwenn HansenRSU20,000353,600
Arthur SandsOption75,00018.5
Arthur SandsOption333,3348.72
Christine RingRSU4,00070,720
Arthur SandsOption12,50018.89
Hans van HouteRSU2,88751,042
Hans van HouteRSU4,00070,720
Christine RingRSU1,92534,034
Hans van HouteRSU22,500397,800
Gwenn HansenOption56,25017.12
Hans van HouteOption7,40910.83
Christine RingOption7,40910.83
Hans van HouteOption4,32919.49
Hans van HouteOption62,5008.72
Gwenn HansenOption62,5008.72
Christine RingRSU22,500397,800
Christine RingOption7,53718.5
Gwenn HansenOption11,30618.5
Christine RingOption2,88619.49
05

Incentive-plan design — the Compensation Discussion & Analysis

An appropriate, well-designed compensation program should align executive interests with the drivers of growth and stockholder returns by supporting the achievement of our primary business goals. Further, our compensation program must enable us to attract and retain employees whose talents, expertise and leadership can drive our success and sustained growth in long-term stockholder value.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAon plc (Human Capital Solutions practice)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1572,458,9206,895,394573,20491.31%Passed
20252025-05-1949,788,97511,341,36592,54081.45%Passed
20242024-05-2030,364,0014,022,08277,42888.3%Passed
20232023-05-0419,907,44812,499,8301,644,71561.43%Passed
20222022-05-0534,032,3851,380,7606,87896.1%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1591.31%a
20252025-05-1981.45%b
20242024-05-2088.3%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.

c. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)23 : 1
CEO total compensation$6,374,138
Median employee compensation$274,252
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Roy D. BaynesIndependent · Clinical and Commercialization (Chair) · Newly elected$44,479$0$624,307$0$668,786
Roger DanseyIndependent · Clinical and Commercialization · Newly elected4,7920416,8920421,684
Julia P. GregoryIndependent · Board Chair · Audit · Nominating/Governance101,4580157,5091258,968
Paul M. SilvaIndependent · Audit (Chair) · Compensation72,8130157,5090230,322
Judith A. ReinsdorfIndependent · Audit · Nominating/Governance (Chair)71,5630157,5090229,072
David L. LaceyIndependent · Compensation (Chair) · Clinical and Commercialization69,0630157,509-1226,571
Edward C. SaltzmanIndependent · Compensation · Clinical and Commercialization62,7080157,5091220,218
Anil KapurIndependent · Nominating/Governance · Clinical and Commercialization60,4170157,5090217,926
Lori A. KunkelIndependent · Departed during FY50,9380157,5090208,447
Arthur T. SandsEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$157,509
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 20,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$538,231
Equity awards (grant-date value)$0
All other compensation$1
Total cost of the board$538,232

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Nurix Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Gritstone bio, Inc. (GRTS) Mersana Therapeutics, Inc. (MRSN)101 Celldex Therapeutics, Inc. (CLDX)102 RAPT Therapeutics, Inc. (RAPT) Kezar Life Sciences, Inc. (KZR)

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Nurix Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1RAPT Therapeutics, Inc.2024Brian Wong$630,000$0$5,927,297$416,000$6,979,539
2Nurix Therapeutics2025Arthur Sands674,58405,166,196510,0006,374,138
3Celldex Therapeutics, Inc.2025Anthony Marucci785,80404,027,59005,366,709
4Mersana Therapeutics, Inc.2024Michael Huber632,500133,635518,044322,5751,613,754
Gritstone bio, Inc.not in coverage universe
Kezar Life Sciences, Inc.not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Nurix Therapeutics125%Options 100not disclosedAon plc (Human Capital Solutions practice)
Celldex Therapeutics, Inc.100%Options 100not disclosedAon (Human Capital Solutions practice, a division of Aon plc)
Gritstone bio, Inc.not disclosednot disclosednot disclosednot disclosed
Kezar Life Sciences, Inc.not disclosednot disclosednot disclosednot disclosed
Mersana Therapeutics, Inc.85%Options 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
RAPT Therapeutics, Inc.120%Options 100not disclosedAon plc/Radford

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Arthur SandsDEF 14A2026-03-270001140361-26-011492Section “Summary Compensation Table”. As printed: 6,374,138. Filing ↗machine: r2 · c21 · span 570227–570236
2Section 01, Gwenn HansenDEF 14A2026-03-270001140361-26-011492Section “Summary Compensation Table”. As printed: 2,498,124. Filing ↗machine: r8 · c21 · span 593328–593337
3Section 01, Hans van HouteDEF 14A2026-03-270001140361-26-011492Section “Summary Compensation Table”. As printed: 2,296,503. Filing ↗machine: t131 · r5 · c21 · span 581960–581969
4Section 01, Christine RingDEF 14A2026-03-270001140361-26-011492Section “Summary Compensation Table”. As printed: 2,263,337. Filing ↗machine: r11 · c21 · span 605140–605149
5Section 03, Gwenn Hansen OPTIONDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r9 · c30 · span 673933–673940
6Section 03, Gwenn Hansen RSUDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r10 · c30 · span 678667–678674
7Section 03, Arthur Sands OPTIONDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r4 · c30 · span 647446–647455
8Section 03, Gwenn Hansen RSUDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r11 · c30 · span 684196–684203
9Section 03, Christine Ring RSUDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r14 · c30 · span 699098–699105
10Section 03, Christine Ring OPTIONDEF 14A2026-03-270001140361-26-011492Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r13 · c30 · span 694628–694635
11Section 07, pay ratioDEF 14A2026-03-270001140361-26-011492Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗machine: span 1069852–1069856
12Section 08, Roy D. BaynesDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 668,786. Filing ↗machine: t70 · r3 · c9 · span 243391–243398
13Section 08, Roger DanseyDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 421,684. Filing ↗machine: t70 · r4 · c9 · span 245435–245442
14Section 08, Julia P. GregoryDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 258,968. Filing ↗machine: t70 · r2 · c9 · span 241584–241591
15Section 08, Paul M. SilvaDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 230,322. Filing ↗machine: t70 · r10 · c9 · span 256805–256812
16Section 08, Judith A. ReinsdorfDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 229,072. Filing ↗machine: t70 · r8 · c9 · span 253088–253095
17Section 08, David L. LaceyDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 226,571. Filing ↗machine: t70 · r7 · c9 · span 251037–251044
18Section 08, Edward C. SaltzmanDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 220,218. Filing ↗machine: t70 · r9 · c9 · span 254862–254869
19Section 08, Anil KapurDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 217,926. Filing ↗machine: t70 · r5 · c9 · span 247201–247208
20Section 08, Lori A. KunkelDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 208,447. Filing ↗machine: t70 · r6 · c9 · span 249261–249268
21Section 08, Arthur T. SandsDEF 14A2026-03-270001140361-26-011492Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Christine Ring 2026-04-02Form 42026-04-020001817199-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Gwenn Hansen 2026-04-30Form 42026-04-300001817160-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Christine Ring 2026-04-30Form 42026-04-300001817199-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Hans van Houte 2026-04-30Form 42026-04-300001817217-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Christine Ring 2026-05-01Form 42026-05-010001817199-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Christine Ring 2026-05-04Form 42026-05-040001817199-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Hans van Houte 2026-05-05Form 42026-05-050001817217-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Hans van Houte 2026-05-05Form 42026-05-050001817217-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Julia P. Gregory 2026-05-15Form 42026-05-150001226675-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Roy D. Baynes 2026-05-15Form 42026-05-150001680739-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Paul M. Silva 2026-05-15Form 42026-05-150001446372-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Edward C. Saltzman 2026-05-15Form 42026-05-150001946233-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Anil Kapur 2026-05-15Form 42026-05-150001730703-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Judith A. Reinsdorf 2026-05-15Form 42026-05-150001305361-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, David L. Lacey 2026-05-15Form 42026-05-150001734422-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Roger Dansey 2026-05-15Form 42026-05-150001741836-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Christine Ring 2026-06-02Form 42026-06-020001817199-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Christine Ring 2026-06-02Form 42026-06-020001817199-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Christine Ring 2026-06-02Form 42026-06-020001817199-26-000020Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Gwenn Hansen 2026-06-25Form 42026-06-250001817160-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Christine Ring 2026-06-25Form 42026-06-250001817199-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Christine Ring 2026-06-25Form 42026-06-250001817199-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Christine Ring 2026-06-25Form 42026-06-250001817199-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Christine Ring 2026-06-25Form 42026-06-250001817199-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Christine Ring 2026-06-25Form 42026-06-250001817199-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Christine Ring 2026-07-02Form 42026-07-020001817199-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Christine Ring 2026-07-02Form 42026-07-020001817199-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Christine Ring 2026-07-02Form 42026-07-020001817199-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Christine Ring 2026-07-02Form 42026-07-020001817199-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Christine Ring 2026-07-02Form 42026-07-020001817199-26-000024Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Christine Ring 2026-07-30Form 42026-07-300001817199-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Hans van Houte 2026-07-30Form 42026-07-300001817217-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Gwenn Hansen 2026-07-30Form 42026-07-300001817160-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
91Section 06, 2026 voteForm 8-K2026-05-150001549595-26-000028Item 5.07 · say-on-pay result. As reported: 91.31% (votes for as printed: 72,458,920). Filing ↗
92Section 06, 2025 voteForm 8-K2025-05-190001549595-25-000067Item 5.07 · say-on-pay result. As reported: 81.45% (votes for as printed: 49,788,975). Filing ↗
93Section 06, 2024 voteForm 8-K2024-05-210001549595-24-000073Item 5.07 · say-on-pay result. As reported: 88.3% (votes for as printed: 30,364,001). Filing ↗
94Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
95Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
96Section 09b board cost (computed)ComputedcomputedCash 538,231 + equity 0 + all other 1 = 538,232, summed across the director compensation table rows.machine: formula: Σ = 538,232
97RAPT Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-140000950170-25-053517CEO total compensation as printed in RAPT Therapeutics, Inc.'s own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861
98Nurix Therapeutics (subject), Section 10b CEO totalDEF 14A2026-03-270001140361-26-011492CEO total compensation as printed in Nurix Therapeutics's own proxy. As printed: 6,374,138. Filing ↗machine: r2 · c21 · span 570227–570236
99Celldex Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-290001104659-26-050884CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866
100Mersana Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197
101Section 10a, Mersana Therapeutics, Inc. reciprocityDEF 14A0001104659-25-040448Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Nurix Therapeutics. Filing ↗
102Section 10a, Celldex Therapeutics, Inc. reciprocityDEF 14A0001104659-26-050884Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Nurix Therapeutics. Filing ↗